Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Deloitte
UBS
Farmers Insurance
Teva
Medtronic
Queensland Health
Federal Trade Commission
Johnson and Johnson
Dow

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,184,220

« Back to Dashboard

Which drugs does patent 6,184,220 protect, and when does it expire?

Patent 6,184,220 protects MOBIC and is included in one NDA.

Protection for MOBIC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-nine patent family members in twenty-four countries.
Summary for Patent: 6,184,220
Title: Oral suspension of pharmaceutical substance
Abstract:The present invention relates to orally administered suspensions of pharmaceutical active substances of the NSAID type, particularly the antirheumatic agent Meloxicam, which are stabilized by the addition of small amounts of highly dispersed silicon dioxide using high shear forces and adding small amounts of hydrophilic polymers to form a three-dimensional siloid structure, and a process for the preparation thereof.
Inventor(s): Turck; Dietrich (Ulm, DE), Schmelmer; Veit (Biberach, DE)
Assignee: Boehringer Ingelheim Pharma KG (Ingelheim, DE)
Application Number:09/276,208
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Drugs Protected by US Patent 6,184,220

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim MOBIC meloxicam SUSPENSION;ORAL 021530-001 Jun 1, 2004 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,184,220

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
98105568Mar 27, 1998

Non-Orange Book US Patents Family Members for Patent 6,184,220

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,682,747 Process for preparing an oral suspension of a pharmaceutical substance ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,184,220

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 016196 ➤ Try a Free Trial
Austria 225648 ➤ Try a Free Trial
Australia 3147099 ➤ Try a Free Trial
Australia 762464 ➤ Try a Free Trial
Brazil 9909189 ➤ Try a Free Trial
Canada 2326048 ➤ Try a Free Trial
China 1150888 ➤ Try a Free Trial
China 1295462 ➤ Try a Free Trial
Colombia 5070601 ➤ Try a Free Trial
Germany 59903023 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Farmers Insurance
Merck
Cerilliant
Chubb
Express Scripts
Covington
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot